On the ground in Hopewell, New Jersey, stands the $800 million flagship that BeiGene opened in July, all clinical R&D and manufacturing muscle. By Thursday, November 14, 2024, the company that built it had decided the name over the door no longer fit: the cancer drug maker, an identity formed at its 2010 inception, is now BeOne Medicines Ltd.
The reasoning, laid out in a morning release, is almost charmingly literal. The “Be” component, the company said, “represents the fundamental goal of any patient with cancer”, simply to be free of disease, while “One” speaks to unity of company and mission to cure cancer. The new logo renders “One” as “Onc” in red, meant to “illustrate our redoubled commitment to oncology”, and “ONC” becomes the Nasdaq ticker once shareholders sign off, usually a formality. A power button hides inside the final e, and the button tilts, because the pathway of creating cancer medicines is “not always straight-forward as we push the boundaries of science.”
The scene behind the rebrand is commercial gravity. Brukinsa, the star blood-cancer therapy, more than doubled sales last financial year, passing the blockbuster threshold at $1.3 billion. Tevimbra, the solid-tumor PD-1 inhibitor also known as tislelizumab, is being pushed behind it. Chief executive John Oyler, a co-founder, put the scale plainly: the company has already reached more than 1.4 million patients, and “this year we will bring more than 10 new potential medicines into the clinic.” Headquarters sit in China, Switzerland and the United States at once.
Residents describe the subtext as loudly as the text. One trade publication’s shorthand: the global pharma company whose name rhymes with the capital of China wants the world to understand that it is not actually a Chinese company, an unlinking of the brand from its Beijing-inflected roots at a moment when Western biotech politics are unforgiving. The company’s own words stay on medicine: a commitment to “playing a critical role and unifying the global community in the fight against cancer”, and to making treatments more accessible and affordable.
Nor is the move eccentric. Roughly a dozen biotechs and several Big Pharmas have renamed in recent years: GSK slimmed from GlaxoSmithKline, Bristol Myers Squibb dropped its hyphen, Pfizer and Sanofi took new corporate branding, Sanofi also burying Aventis. By nightfall on rebrand day, a fourteen-year-old name was already corporate history, and Oyler was looking to what he called the next chapter of growth as BeOne.
Sources
- BeiGene becomes BeOne Medicines in major rebrand
- BeiGene rebrands as BeOne Medicines, dropping name’s link to China
